[{"from": "human", "value": "Provide a description of this molecule. [C][C@@H1][C][C][N][Branch2][Ring1][=Branch1][C][C@@H1][Ring1][=Branch1][N][Branch1][C][C][C][=N][C][=N][C][=C][Ring1][=Branch1][C][=C][N][Ring1][Branch1][C][=Branch1][C][=O][C][C][#N]"}, {"from": "gpt", "value": "The molecule is an orally available inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha and -beta, and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation."}]